Presenting characteristics by BAALC expression group
. | Low BAALC n = 43 . | High BAALC n = 43 . | P . |
---|---|---|---|
Age, y, median (range) | 48 (20-59) | 45 (18-59) | .21 |
Sex, n (% males) | 24 (56) | 22 (51) | .83 |
Hemoglobin level, g/dL, median (range) | 8.95 (4.7-12.8) | 8.7 (4.6-12.9) | .84 |
Platelet count, ×109/L, median (range) | 50 (5-311) | 61 (7-378) | .71 |
WBC, ×109/L, median (range) | 31.6 (1.4-295.0) | 13.8 (0.8-96.5) | .03 |
Percent blood blasts, median (range) | 53 (0-97) | 46 (0-95) | .33 |
Percent bone marrow blasts, median (range) | 58 (28-90) | 55 (26-90) | .46 |
Race, n (%) | .10 | ||
White | 35 (81) | 40 (93) | |
Hispanic | 6 (14) | 1 (2) | |
African American | 1 (2) | 1 (2) | |
Oriental | 1 (2) | 0 (0) | |
Other | 0 (0) | 1 (2) | |
FAB classification, n (%) | .03 | ||
M0 | 1 (2) | 2 (5) | |
M1 | 7 (17) | 11 (28) | |
M2 | 12 (29) | 16 (40) | |
M4 | 12 (29) | 9 (23) | |
M5 | 10 (24) | 1 (3) | |
M6 | 0 (0) | 1 (3) | |
Unknown | 1 | 3 | |
Gum hypertrophy, n (%) | 10 (23) | 6 (14) | .41 |
Lymphadenopathy, n (%) | 3 (7) | 5 (12) | .71 |
Skin infiltrates, n (%) | 8 (19) | 3 (7) | .20 |
Hepatomegaly, n (%) | 2 (5) | 2 (5) | .99 |
Splenomegaly, n (%) | 1 (2) | 4 (9) | .36 |
FLT3 genotype, n (%) | |||
FLT3WT/WT | 35 (81) | 35 (81) | .99 |
FLT3ITD/WT | 8 (19) | 8 (19) |
. | Low BAALC n = 43 . | High BAALC n = 43 . | P . |
---|---|---|---|
Age, y, median (range) | 48 (20-59) | 45 (18-59) | .21 |
Sex, n (% males) | 24 (56) | 22 (51) | .83 |
Hemoglobin level, g/dL, median (range) | 8.95 (4.7-12.8) | 8.7 (4.6-12.9) | .84 |
Platelet count, ×109/L, median (range) | 50 (5-311) | 61 (7-378) | .71 |
WBC, ×109/L, median (range) | 31.6 (1.4-295.0) | 13.8 (0.8-96.5) | .03 |
Percent blood blasts, median (range) | 53 (0-97) | 46 (0-95) | .33 |
Percent bone marrow blasts, median (range) | 58 (28-90) | 55 (26-90) | .46 |
Race, n (%) | .10 | ||
White | 35 (81) | 40 (93) | |
Hispanic | 6 (14) | 1 (2) | |
African American | 1 (2) | 1 (2) | |
Oriental | 1 (2) | 0 (0) | |
Other | 0 (0) | 1 (2) | |
FAB classification, n (%) | .03 | ||
M0 | 1 (2) | 2 (5) | |
M1 | 7 (17) | 11 (28) | |
M2 | 12 (29) | 16 (40) | |
M4 | 12 (29) | 9 (23) | |
M5 | 10 (24) | 1 (3) | |
M6 | 0 (0) | 1 (3) | |
Unknown | 1 | 3 | |
Gum hypertrophy, n (%) | 10 (23) | 6 (14) | .41 |
Lymphadenopathy, n (%) | 3 (7) | 5 (12) | .71 |
Skin infiltrates, n (%) | 8 (19) | 3 (7) | .20 |
Hepatomegaly, n (%) | 2 (5) | 2 (5) | .99 |
Splenomegaly, n (%) | 1 (2) | 4 (9) | .36 |
FLT3 genotype, n (%) | |||
FLT3WT/WT | 35 (81) | 35 (81) | .99 |
FLT3ITD/WT | 8 (19) | 8 (19) |